AIM: To evaluate whether expression of L-type amino acid transporter 1 (LAT1) in pretreatment rectal cancer biopsies is predictive of tumour response to neoadjuvant hyperthermo-chemoradiotherapy (HCRT). PATIENTS AND METHODS: Forty-four patients with rectal adenocarcinoma who received neoadjuvant HCRT were investigated. LAT1 expression was immunohistochemically evaluated using pretreatment biopsies. The operation was performed after 2-3 months following HCRT and each resected specimen was graded by the histological criteria of the Japanese Classification of Colorectal Carcinoma. RESULTS: A positive LAT1 expression was recognized in 50.0% (22/44) of patients. Resected specimens were divided into 2 groups according to the histological grading criteria: good response (n=29) and poor response (n=15). LAT1-negative tumours had an 81.8% probability of good response and 18.2% probability of poor response. LAT1 expression showed marginally significant association with response to HCRT (p=0.05). CONCLUSION: LAT1 may be a useful predictive marker of response to HCRT in rectal cancer.
AIM: To evaluate whether expression of L-type amino acid transporter 1 (LAT1) in pretreatment rectal cancer biopsies is predictive of tumour response to neoadjuvant hyperthermo-chemoradiotherapy (HCRT). PATIENTS AND METHODS: Forty-four patients with rectal adenocarcinoma who received neoadjuvant HCRT were investigated. LAT1 expression was immunohistochemically evaluated using pretreatment biopsies. The operation was performed after 2-3 months following HCRT and each resected specimen was graded by the histological criteria of the Japanese Classification of Colorectal Carcinoma. RESULTS: A positive LAT1 expression was recognized in 50.0% (22/44) of patients. Resected specimens were divided into 2 groups according to the histological grading criteria: good response (n=29) and poor response (n=15). LAT1-negative tumours had an 81.8% probability of good response and 18.2% probability of poor response. LAT1 expression showed marginally significant association with response to HCRT (p=0.05). CONCLUSION:LAT1 may be a useful predictive marker of response to HCRT in rectal cancer.
Authors: Evan Augustyn; Karissa Finke; Arik A Zur; Logan Hansen; Nathan Heeren; Huan-Chieh Chien; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas Journal: Bioorg Med Chem Lett Date: 2016-04-11 Impact factor: 2.823
Authors: Colton Hall; Hannah Wolfe; Alyssa Wells; Huan-Chieh Chien; Claire Colas; Avner Schlessinger; Kathleen M Giacomini; Allen A Thomas Journal: Bioorg Med Chem Lett Date: 2019-06-20 Impact factor: 2.823
Authors: Arik A Zur; Huan-Chieh Chien; Evan Augustyn; Andrew Flint; Nathan Heeren; Karissa Finke; Christopher Hernandez; Logan Hansen; Sydney Miller; Lawrence Lin; Kathleen M Giacomini; Claire Colas; Avner Schlessinger; Allen A Thomas Journal: Bioorg Med Chem Lett Date: 2016-09-03 Impact factor: 2.823
Authors: Ryan S Youland; Gaspar J Kitange; Timothy E Peterson; Deanna H Pafundi; Judi A Ramiscal; Jenny L Pokorny; Caterina Giannini; Nadia N Laack; Ian F Parney; Val J Lowe; Debra H Brinkmann; Jann N Sarkaria Journal: J Neurooncol Date: 2012-10-20 Impact factor: 4.130